Emmessar Biotech & Nutrition Ltd
Emmessar Biotech & Nutrition Ltd (EMMESSA) last reported results for the quarter ended Jun 2026, with sales of ₹0.06 crore and net profit of ₹0.13 crore. The stock last traded at ₹23.7, a market capitalisation of ₹11.8 crore, on a P/E of 30.4. Over the past 52 weeks the stock has ranged between ₹18.4 and ₹33.4. Figures are as of 6 Oct 2026 and are not real time.
Emmessar Biotech & Nutrition Ltd share price and key metrics
- Current price
- ₹23.7
- Market cap
- ₹11.8 cr
- Stock P/E
- 30.4
- Book value
- ₹16.2
- ROE
- 5.56%
- ROCE
- 7.33%
- Dividend yield
- 0.00%
- 52w high / low
- 33.4/18.4
Metrics as of 6 Oct 2026. Not real time.
Track Emmessar Biotech & Nutrition Ltd
Cruxal reads every Emmessar Biotech & Nutrition Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Emmessar Biotech & Nutrition Ltd growth and returns
- 10 Years
- -15%
- 5 Years
- -44%
- 3 Years
- -29%
- TTM
- -48%
- 10 Years
- 14%
- 5 Years
- -21%
- 3 Years
- -4%
- TTM
- -3%
- 10 Years
- 1%
- 5 Years
- -7%
- 3 Years
- -3%
- 1 Year
- -29%
- 10 Years
- 15%
- 5 Years
- 7%
- 3 Years
- 7%
- Last Year
- 6%
Emmessar Biotech & Nutrition Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹0.06 cr, down 33.3% from ₹0.09 cr a year earlier. Net profit was ₹0.13 cr, down 23.5% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 0.34 | 0.1 | 0.1 | 0.09 | 0.09 | 0.09 | 0.09 | 0.06 |
| Expenses | 0.42 | 0.38 | 0.43 | 0.36 | 0.46 | 0.43 | 0.46 | 0.41 |
| Operating profit | -0.08 | -0.28 | -0.33 | -0.27 | -0.37 | -0.34 | -0.37 | -0.35 |
| OPM % | -23.53% | -280.00% | -330.00% | -300.00% | -411.11% | -377.78% | -411.11% | -583.33% |
| Other income | 0.51 | 0.43 | 0.61 | 0.53 | 0.54 | 0.49 | 0.47 | 0.54 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 | 0.03 | 0.02 |
| Profit before tax | 0.41 | 0.13 | 0.26 | 0.24 | 0.14 | 0.12 | 0.07 | 0.17 |
| Tax % | 31.71% | 84.62% | 126.92% | 25.00% | 21.43% | 8.33% | 57.14% | 17.65% |
| Net profit | 0.28 | 0.02 | -0.07 | 0.17 | 0.11 | 0.12 | 0.03 | 0.13 |
| EPS (₹) | 0.56 | 0.04 | -0.14 | 0.34 | 0.22 | 0.24 | 0.06 | 0.26 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Emmessar Biotech & Nutrition Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2.61 | 1.27 | 0.63 | 3.4 | 6.99 | 0.36 | 1.02 | 0.56 | 0.61 | 0.37 | 0.33 |
| Operating profit | 0.23 | -0.4 | -0.64 | -0.41 | 0.84 | -0.9 | -0.69 | -1.08 | -0.95 | -1.36 | -1.43 |
| OPM % | 8.81% | -31.50% | -101.59% | -12.06% | 12.02% | -250.00% | -67.65% | -192.86% | -155.74% | -367.57% | -433.33% |
| Net profit | 1.19 | 0.91 | 0.53 | 0.75 | 1.45 | 0.48 | 0.5 | 0.75 | 0.32 | 0.44 | 0.39 |
| EPS (₹) | 2.38 | 1.82 | 1.06 | 1.50 | 2.90 | 0.96 | 1.00 | 1.50 | 0.64 | 0.88 | 0.78 |
TTM is the trailing twelve months to the most recent quarter.
Emmessar Biotech & Nutrition Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Reserves | -2.91 | -2.01 | -1.49 | -0.73 | 0.70 | 1.17 | 1.67 | 2.41 | 2.71 | 3.12 |
| Borrowings | 0.00 | 0.00 | 0.07 | 0.00 | 0.00 | 0.00 | 0.08 | 0.11 | 0.00 | 0.00 |
| Other liabilities | 1.13 | 0.92 | 1.59 | 1.86 | 2.11 | 1.04 | 1.19 | 1.23 | 1.71 | 1.66 |
| Total liabilities | 3.22 | 3.91 | 5.17 | 6.13 | 7.81 | 7.21 | 7.94 | 8.75 | 9.42 | 9.78 |
| Fixed assets | 0.72 | 2.25 | 1.99 | 1.91 | 1.86 | 2.07 | 2.00 | 1.91 | 1.81 | 1.72 |
| CWIP | 0.80 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Other assets | 1.69 | 1.65 | 3.17 | 4.21 | 5.94 | 5.13 | 5.93 | 6.83 | 7.60 | 8.05 |
| Total assets | 3.22 | 3.91 | 5.17 | 6.13 | 7.81 | 7.21 | 7.94 | 8.75 | 9.42 | 9.78 |
As reported by the company. Total assets equal total liabilities by construction.
Emmessar Biotech & Nutrition Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 0.75 | 0.74 | 0.39 | 1.03 | 0.47 | 2.27 | 0.38 | 0.64 | 0.22 | 0.27 |
| Cash from investing | -0.74 | -0.69 | -0.37 | -1.06 | 0.01 | -2.61 | -0.55 | -0.64 | -0.23 | -0.26 |
| Cash from financing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Net cash flow | 0.01 | 0.05 | 0.01 | -0.03 | 0.48 | -0.34 | -0.17 | 0.00 | 0.00 | 0.02 |
| Free cash flow | -0.06 | -0.04 | 0.39 | 1.03 | 0.47 | 1.96 | 0.35 | 0.64 | 0.22 | 0.26 |
| CFO / operating profit | 343% | -198% | -61% | -251% | 68% | -284% | -46% | -57% | -25% | -11% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Emmessar Biotech & Nutrition Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 80.00% | 31.50% | 17.66% | 25.48% | 45.14% | 15.67% | 15.02% | 11.35% | 12.61% | 7.33% |
| Debtor days | 5.59 | 8.62 | 23.17 | 3.22 | 141.51 | 10.14 | 3.58 | 13.04 | 11.97 | 19.73 |
| Inventory days | 121.67 | 52.14 | 2,049.62 | 272.56 | 7.24 | 196.54 | 127.75 | 164.25 | 230.53 | 405.56 |
| Days payable | 76.04 | 5.79 | 1,628.46 | 189.61 | 51.70 | 56.15 | 0.00 | 18.25 | 0.00 | 40.56 |
| Cash conversion cycle | 51.22 | 54.97 | 444.33 | 86.18 | 97.05 | 150.52 | 131.33 | 159.04 | 242.49 | 384.73 |
| Working capital days | 85.31 | 175.31 | 457.70 | 30.06 | 79.37 | -60.83 | 114.51 | 91.25 | 29.92 | 88.78 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Emmessar Biotech & Nutrition Ltd shareholding pattern
Promoters held 59.53% at Jun 2026, broadly unchanged since Jun 2025. DIIs 0.19%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 59.53% | 59.53% | 59.53% | 59.53% | 59.53% | 59.53% | 59.53% | 59.53% |
| DIIs | 0.19% | 0.19% | 0.19% | 0.19% | 0.19% | 0.19% | 0.19% | 0.19% |
| Public | 40.27% | 40.28% | 40.27% | 40.28% | 40.28% | 40.27% | 40.26% | 40.26% |
| No. of shareholders | 6,936 | 7,186 | 7,180 | 7,173 | 7,350 | 7,244 | 7,172 | 7,136 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Emmessar Biotech & Nutrition Ltd corporate filings
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Company Updatelow impact
Cruxal's analysis: Please refer attachment
Read the full analysis - Emmessar Biotech files for re-application of shares via newspaper advertisementCompany Updatelow impact
Cruxal's analysis: The company, with a market cap of approximately 11.69 crore, has announced a newspaper…
Read the full analysis - Closure of Trading WindowInsider Trading / SASTlow impact
Cruxal's analysis: Please refer attachment
Read the full analysis - Emmessar Biotech & Nutrition Limited concludes 34th AGM; re-appoints Managing Director and Whole-time Director for 5-year termsAGM/EGMlow impact
Cruxal's analysis: Emmessar Biotech & Nutrition Limited has successfully concluded its 34th Annual General…
Read the full analysis - Emmessar Biotech & Nutrition Limited concludes 34th Annual General Meeting; re-appoints key management personnelAGM/EGMlow impact
Cruxal's analysis: Emmessar Biotech & Nutrition Limited has successfully concluded its 34th Annual General…
Read the full analysis - Emmessar Biotech & Nutrition Ltd: Routine Newspaper Advertisement DisclosureCompany Updatelow impact
Cruxal's analysis: Emmessar Biotech & Nutrition Ltd has released a routine newspaper advertisement as part…
Read the full analysis - Emmessar Biotech & Nutrition Limited Announces 34th Annual General Meeting to be Held via Video Conferencing on September 29, 2026Company Updatelow impact
Cruxal's analysis: Emmessar Biotech & Nutrition Limited has issued a formal notice for its 34th Annual…
Read the full analysis - Emmessar Biotech & Nutrition Ltd publishes routine newspaper advertisementCompany Updatelow impact
Cruxal's analysis: The company has released a routine newspaper advertisement as part of its statutory…
Read the full analysis - Emmessar Biotech & Nutrition reports Q1 FY27 net profit of 13.15 lakh, impacted by declining core healthcare revenueBoard Meetingmedium impact
Cruxal's analysis: Emmessar Biotech & Nutrition Limited reported a net profit of 13.15 lakh for the quarter…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.